MC2 Therapeutics appoints Trine Ahlgreen as new CEO
Ella Day | May 27, 2025 | Appointment | Research and Development, Sales and Marketing | CEO, Corporate, MC2 Therapeutics, Skin, inflammatory skin conditions
MC2 Therapeutics, a Danish pharma company focused on topical therapies for inflammatory skin conditions, has appointed Trine Ahlgreen as CEO. This intends to support the MC2’s goal to globally commercialise its PAD Technology and lead asset, Wynzora Cream.
Ahlgreen brings a rich background in pharma leadership to MC2, having led teams and business developments across Europe, the US and Japan. Most recently, she built the commercial and business development infrastructure focused on dermatology at Swiss biotech Micros Pharmaceuticals. Prior, Ahlgreen played key roles in several product launches over her twenty years spent at Novo Nordisk, including the launches of Ozempic, Rybelsus and the global cardiovascular indication for GLP-1.
Previously and since its inception, Jesper J Lange served as CEO of the company. Under his leadership, the company developed Wynzora Cream, fostered global partnerships and established commercial manufacturing, with three contract manufacturing organisation in both Europe and the US.
Commenting on her appointment, Ahlgreen said: “I’m honoured to lead the next phase of the company’s growth, focused on realising the potential of Wynzora Cream, while exploring new opportunities through our PAD Technology formulation platform with selected partners.”
The PAD Technology is MC2’s formulation and delivery system used to support the development of its topical therapies such as Wynzora Cream, a treatment for plaque psoriasis.
Ella Day
27/5/25
Related Content
MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora
Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and …
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
FibroGen rocked by unexpected death of CEO Thomas B Neff
In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, …
